Publications 2025

Høyvik AJK, Kvassheim M, Ma LW, Wiig E, Hillestad T, Revheim ME, Liukaityte R, Bruland Ø, Juzeniene A (2025)
Therapeutic evaluation of [²¹²Pb]Pb-AB001 and [¹⁷⁷Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer
Eur J Nucl Med Mol Imaging (in press)
DOI 10.1007/s00259-025-07330-y, PubMed 40397137

Publications 2022

Nilsen A, Hillestad T, Skingen VE, Aarnes EK, Fjeldbo CS, Hompland T, Evensen TS, Stokke T, Kristensen GB, Grallert B, Lyng H (2022)
miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer
Mol Oncol, 16 (6), 1402-1419
DOI 10.1002/1878-0261.13184, PubMed 35064630

Publications 2020

Fjeldbo CS, Hompland T, Hillestad T, Aarnes EK, Günther CC, Kristensen GB, Malinen E, Lyng H (2020)
Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity
EBioMedicine, 57, 102841
DOI 10.1016/j.ebiom.2020.102841, PubMed 32580139

Hillestad T, Hompland T, Fjeldbo CS, Skingen VE, Salberg UB, Aarnes EK, Nilsen A, Lund KV, Evensen TS, Kristensen GB, Stokke T, Lyng H (2020)
MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer
Cancer Res, 80 (18), 3993-4003
DOI 10.1158/0008-5472.CAN-20-0950, PubMed 32606004